Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality

Nicole Brüchert, Nirmala Mavila, Peter Boknik, Hideo A. Baba, Larissa Fabritz, Ulrich Gergs, Uwe Kirchhefer, Paulus Kirchhof, Marek Matus, Wilhelm Schmitz, Anna A. DePaoli-Roach, Joachim Neumann

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cardiac-specific overexpression of the catalytic subunit of protein phosphatase type 1 (PP1) in mice results in hypertrophy, depressed contractility, propensity to heart failure, and premature death. To further address the role of PP1 in heart function, PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2140). Protein phosphatase activity was increased in PP1 mice but was normalized in double transgenic (DT) mice. The maximal rates of contraction (+dP/dt) and of relaxation (-dP/dt) were reduced in catheterized PP1 mice but normalized in DT mice. Similar contractile abnormalities were observed in isolated, perfused work-performing hearts and in whole animals by means of echocardiography. The increased absolute and relative heart weights observed in PP1 mice were normalized in DT mice. Histological analyses indicated that PP1 mice had significant cardiac fibrosis, which was absent in DT mice. Furthermore, PP1 mice exhibited an age-dependent increase in mortality, which was abrogated in DT mice. These results indicate that I-2 overexpression prevents the detrimental effects of PP1 overexpression in the heart and further underscore the fundamental role of PP1 in cardiac function. Therefore, PP1 inhibitors such as I-2 could offer new therapeutic options to ameliorate the deleterious effects of heart failure.

Original languageEnglish (US)
Pages (from-to)H1539-H1546
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume295
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Protein Phosphatase 1
Cardiomegaly
Mortality
Transgenic Mice
Heart Failure
Premature Mortality
Phosphoprotein Phosphatases
Hypertrophy
Echocardiography
Fibrosis

Keywords

  • Contractility
  • Drug target
  • Heart failure
  • Transgenic mice

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. / Brüchert, Nicole; Mavila, Nirmala; Boknik, Peter; Baba, Hideo A.; Fabritz, Larissa; Gergs, Ulrich; Kirchhefer, Uwe; Kirchhof, Paulus; Matus, Marek; Schmitz, Wilhelm; DePaoli-Roach, Anna A.; Neumann, Joachim.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 295, No. 4, 01.10.2008, p. H1539-H1546.

Research output: Contribution to journalArticle

Brüchert, N, Mavila, N, Boknik, P, Baba, HA, Fabritz, L, Gergs, U, Kirchhefer, U, Kirchhof, P, Matus, M, Schmitz, W, DePaoli-Roach, AA & Neumann, J 2008, 'Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality', American Journal of Physiology - Heart and Circulatory Physiology, vol. 295, no. 4, pp. H1539-H1546. https://doi.org/10.1152/ajpheart.00515.2008
Brüchert, Nicole ; Mavila, Nirmala ; Boknik, Peter ; Baba, Hideo A. ; Fabritz, Larissa ; Gergs, Ulrich ; Kirchhefer, Uwe ; Kirchhof, Paulus ; Matus, Marek ; Schmitz, Wilhelm ; DePaoli-Roach, Anna A. ; Neumann, Joachim. / Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. In: American Journal of Physiology - Heart and Circulatory Physiology. 2008 ; Vol. 295, No. 4. pp. H1539-H1546.
@article{6f833772cf1949f994514049d62b799f,
title = "Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality",
abstract = "Cardiac-specific overexpression of the catalytic subunit of protein phosphatase type 1 (PP1) in mice results in hypertrophy, depressed contractility, propensity to heart failure, and premature death. To further address the role of PP1 in heart function, PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2140). Protein phosphatase activity was increased in PP1 mice but was normalized in double transgenic (DT) mice. The maximal rates of contraction (+dP/dt) and of relaxation (-dP/dt) were reduced in catheterized PP1 mice but normalized in DT mice. Similar contractile abnormalities were observed in isolated, perfused work-performing hearts and in whole animals by means of echocardiography. The increased absolute and relative heart weights observed in PP1 mice were normalized in DT mice. Histological analyses indicated that PP1 mice had significant cardiac fibrosis, which was absent in DT mice. Furthermore, PP1 mice exhibited an age-dependent increase in mortality, which was abrogated in DT mice. These results indicate that I-2 overexpression prevents the detrimental effects of PP1 overexpression in the heart and further underscore the fundamental role of PP1 in cardiac function. Therefore, PP1 inhibitors such as I-2 could offer new therapeutic options to ameliorate the deleterious effects of heart failure.",
keywords = "Contractility, Drug target, Heart failure, Transgenic mice",
author = "Nicole Br{\"u}chert and Nirmala Mavila and Peter Boknik and Baba, {Hideo A.} and Larissa Fabritz and Ulrich Gergs and Uwe Kirchhefer and Paulus Kirchhof and Marek Matus and Wilhelm Schmitz and DePaoli-Roach, {Anna A.} and Joachim Neumann",
year = "2008",
month = "10",
day = "1",
doi = "10.1152/ajpheart.00515.2008",
language = "English (US)",
volume = "295",
pages = "H1539--H1546",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality

AU - Brüchert, Nicole

AU - Mavila, Nirmala

AU - Boknik, Peter

AU - Baba, Hideo A.

AU - Fabritz, Larissa

AU - Gergs, Ulrich

AU - Kirchhefer, Uwe

AU - Kirchhof, Paulus

AU - Matus, Marek

AU - Schmitz, Wilhelm

AU - DePaoli-Roach, Anna A.

AU - Neumann, Joachim

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Cardiac-specific overexpression of the catalytic subunit of protein phosphatase type 1 (PP1) in mice results in hypertrophy, depressed contractility, propensity to heart failure, and premature death. To further address the role of PP1 in heart function, PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2140). Protein phosphatase activity was increased in PP1 mice but was normalized in double transgenic (DT) mice. The maximal rates of contraction (+dP/dt) and of relaxation (-dP/dt) were reduced in catheterized PP1 mice but normalized in DT mice. Similar contractile abnormalities were observed in isolated, perfused work-performing hearts and in whole animals by means of echocardiography. The increased absolute and relative heart weights observed in PP1 mice were normalized in DT mice. Histological analyses indicated that PP1 mice had significant cardiac fibrosis, which was absent in DT mice. Furthermore, PP1 mice exhibited an age-dependent increase in mortality, which was abrogated in DT mice. These results indicate that I-2 overexpression prevents the detrimental effects of PP1 overexpression in the heart and further underscore the fundamental role of PP1 in cardiac function. Therefore, PP1 inhibitors such as I-2 could offer new therapeutic options to ameliorate the deleterious effects of heart failure.

AB - Cardiac-specific overexpression of the catalytic subunit of protein phosphatase type 1 (PP1) in mice results in hypertrophy, depressed contractility, propensity to heart failure, and premature death. To further address the role of PP1 in heart function, PP1 mice were crossed with mice that overexpress a functional COOH-terminally truncated form of PP1 inhibitor-2 (I-2140). Protein phosphatase activity was increased in PP1 mice but was normalized in double transgenic (DT) mice. The maximal rates of contraction (+dP/dt) and of relaxation (-dP/dt) were reduced in catheterized PP1 mice but normalized in DT mice. Similar contractile abnormalities were observed in isolated, perfused work-performing hearts and in whole animals by means of echocardiography. The increased absolute and relative heart weights observed in PP1 mice were normalized in DT mice. Histological analyses indicated that PP1 mice had significant cardiac fibrosis, which was absent in DT mice. Furthermore, PP1 mice exhibited an age-dependent increase in mortality, which was abrogated in DT mice. These results indicate that I-2 overexpression prevents the detrimental effects of PP1 overexpression in the heart and further underscore the fundamental role of PP1 in cardiac function. Therefore, PP1 inhibitors such as I-2 could offer new therapeutic options to ameliorate the deleterious effects of heart failure.

KW - Contractility

KW - Drug target

KW - Heart failure

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=57049177151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049177151&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00515.2008

DO - 10.1152/ajpheart.00515.2008

M3 - Article

C2 - 18689497

AN - SCOPUS:57049177151

VL - 295

SP - H1539-H1546

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 4

ER -